An Open Label Study to Evaluate the Safety of Re-treatment With MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent (Extension Study to ML19070). [EXTENSION OF 700243034]
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 17 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by Roche.
- 08 Dec 2008 Status changed from active, no longer recruiting back to recruiting, according to Roche.